Savara Inc (NASDAQ:SVRA) Given Average Rating of “Buy” by Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have been assigned an average recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $11.17.

A number of equities analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Savara in a research report on Wednesday, August 14th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Monday, September 9th. Guggenheim raised their target price on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Oppenheimer raised their target price on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 26th.

Savara Stock Down 3.2 %

SVRA stock opened at $4.49 on Monday. The company has a current ratio of 11.31, a quick ratio of 11.31 and a debt-to-equity ratio of 0.26. Savara has a twelve month low of $3.12 and a twelve month high of $5.70. The company’s 50 day moving average is $4.38 and its two-hundred day moving average is $4.49. The stock has a market cap of $620.47 million, a P/E ratio of -12.14 and a beta of 0.97.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Research analysts expect that Savara will post -0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co purchased a new position in Savara in the 1st quarter valued at $35,000. Choreo LLC purchased a new stake in shares of Savara during the 2nd quarter worth $59,000. DRW Securities LLC purchased a new stake in shares of Savara during the 2nd quarter worth $62,000. Principal Financial Group Inc. boosted its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC purchased a new stake in shares of Savara during the 2nd quarter worth $105,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.